I-Mab Biopharma gets rights to myeloma drug for China in up to $120 million deal
German biotech MorphoSys (FSE: MOR) has entered into an agreement with Shanghai-based I-Mab Biopharma granting the latter an exclusive regional license to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.
MOR202 is MorphoSys' proprietary investigational antibody against CD38, for which recruitment of a European Phase I/IIa clinical study in relapsed/refractory multiple myeloma has been concluded.
Under the terms of the agreement, I-Mab will assume exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territory.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze